Praxis Precision Medicines, Inc. (PRAX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$345.30-2.04%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Praxis aims for over $20 billion in revenue from key drugs. It has $1.4 billion cash to last until 2028. The company is working to reduce its losses. Positive study results support future sales growth.
Praxis is still losing money and its losses are growing. FDA delayed drug review by three months. The main study failed its key goal. Cash could run low if losses continue.
The price is about 44% below our fair value near $575. The market expects weak near-term growth and ongoing losses. We see potential if the company meets its revenue goals.
Breaks if: cash falls below $1 billion before 2028
Preserve cash and investments to fund operations through 2028, supported by recent capital raises and cash management.
Stated as a priority in 2 of last 2 quarters. Cash and investments remained steady at approximately $1.4 billion from March 31, 2026 to June 30, 2026, supporting management's claim of runway into 2028. The trajectory is delivering as cash levels have been maintained following a significant capital raise.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a volatile management track record, which adds uncertainty to its future performance.
The market appears to be pricing in a low level of fragility, as there are no significant fragility gates triggered. However, PRAX is trading at a premium compared to its peers, reflecting expectations of optionality in its future developments.
Fundamentals are likely to remain weak in the near term, given the company's loss-making status and volatile management. However, there is potential for improvement if management successfully advances its commercial launch readiness and pipeline programs.
The thesis hinges on several factors, including the company's ability to maintain its cash runway, the success of upcoming product launches, and the performance of sector bellwethers that could influence market sentiment. Additionally, broader economic conditions, such as job growth, could impact PRAX's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement. There are no new threats impacting the thesis at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Cash and investments of approximately $1.4 billion as of June 30, 2026 maintains runway into 2028.”
“Cash and investments of approximately $1.4 billion as of March 31, 2026 maintains runway into 2028.”
Breaks if: operating loss worsens beyond -$110 million next year
Breaks if: FDA delays approval beyond 2026-Q4
Breaks if: revenue falls below $15 billion in FY26
Target revenue potential of over $20 billion from four key assets.
In the next 1 to 3 years, PRAX faces a mix of opportunities and challenges that could affect its trajectory. Not investment advice.